Qualigen Therapeutics, Inc. Stock Price

NasdaqCM:QLGN Community·US$4.6m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

QLGN Share Price Performance

US$2.73

-0.91 (-25.00%)

US$2.73

-0.91 (-25.00%)

US$2.73

Mon, 17 Nov 25

Share Pricen/a

QLGN Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks

0 Rewards

View Full Analysis

Qualigen Therapeutics, Inc. Key Details

Last Reported Earnings

Sep 30, 2025

Next Reporting Earnings

n/a

: -4.77
: 0%
: 0%
: 8.4%

View Full Analysis

About QLGN

Founded: 1996
Employees: 4
CEO: Kevin Richardson
WebsiteView website: qlgntx.com

Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996 and is based in Carlsbad, California.